Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Gabe Fernandez who wrote (591)	4/14/1998 7:24:00 PM
From: David Israel-Rosen	Respond to of 1491

Short Stories **** 13:00 -- 14:00 ET (Updated throughout the hour)**** Posted today. Source: Briefing.com Pharmos Corp. (PARS) 3 3/32 +1/16: Jesup & Lamont Securities reiterates "buy" rating on drug developer after company received FDA approval to market Lotemax, an inflammatory eye medication, and Alrex, a seasonal allergic conjunctivitis treatment; proprietary drugs are the first to gain FDA marketing approval in PARS pipeline; expects corporate partner Bausch & Lomb to announce launch in four to six weeks and select marketing partner within the next few months; expects B&L to file product license application for Lotemax and Alrex in Europe within the next three to four months; based on year 2000 earnings projections of $0.28 a share, sets an 18-month price target of between $ 5.50 and $7; 18-month price target assumes no contribution from PARS' head trauma/neuroprotectant HU211 product which has potential to be a blockbuster.....